NIAGARA: perioperative durvalumab with neoadjuvant chemotherapy in MIBC

(2:26)

AEGEAN Trial: Perioperative Durvalumab for NSCLC - OncTalk Lung 2023

(2:22)

NIAGARA: Perioperative Durvalumab Shows Overall Survival Benefit in Muscle-Invasive Bladder Cancer

(5:11)

Perioperative Chemoimmunotherapy in Lung Cancer | NEJM

(2:9)

Researcher comment: Perioperative durvalumab for locally advanced RCC | Moshe Ornstein

(5:18)

Perioperative Durvalumab Appears Safe for Locally Advanced RCC - Medpage Today

(6:52)

AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer

(19:14)

Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC

(1:18)

NIAGRA: Bladder-Sparing Potential of Perioperative Immunotherapy

(3:49)

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

(43:46)

NIAGARA Study Insights: Durvalumab \u0026 Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas

(15:30)

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

(3:44)

MATTERHORN: improved pCR with the use of durvalumab + FLOT in resectable GC/GEJC

(3:9)

Durvalumab Tolerability in Non–Small Cell Lung Cancer

(4:25)

Dr. Simon on Durvalumab for Patients With Lung Cancer

(1:20)

The Use of Durvalumab in Locally Advanced NSCLC

(3:7)

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

(3:53)

Dr. Feldman on Durvalumab for Patients With Lung Cancer

(47)

Phase II study of Durvalumab for patients with NSCLC

(1:13)

Durvalumab: the new standard of care for NSCLC?

(1:24)